Objective To study the expression and function of TCRαβ+ CD3+ CD4-CD8-T (Double negative regulatory T cells,DN Tregs) in peripheral blood of Systemic lupus erythematosus (SLE) patients,and investigate their function in pathogenesis of SLE.Methods TCRαβ+ CD4-CD8 T cells were quantified as percentage of total CD3+ T cells in peripheral blood from 20 SLE patients and 20 healthy controls by flow cytometry.Used ELISA to test the cytokine levels (IFN-γ,TNF-α,IL-6,IL-17A) in the plasma of SLE patients.And analyzed the relationship between the percentage of DN Tregs and cytokines levels.Results The ratio of DN Tregs in TCRαβ+ T cells was significantly increased in SLE patients compared to healthy donors (t=3.54,P＜0.01).The levels of IFN-γ,TNF-α and IL-6 in plasma of SLE patients were higher than healthy donors (t=2.824,2.085,2.304,P＜0.05).The frequency of DN Tregs was found to correlate with IFN-γ (r=0.52,P=0.02) but not TNF-α (r=0.17,P=0.16) and IL-6 (r=0.47,P=0.49).Conclusion This study reveals frequency of DN Tregs in peripheral blood of SLE patients was higher than healthy controls,the frequency of DN Tregs was also found to correlate with IFN-γ levels,which means that DN Tregs may play an important role in pathogenesis of SLE.

Objective To investigate the prevalence of Hepatitis B virus(HBV)infection in systemic lupus erythematosus (SLE)patients.Methods HBV and HCV serological tests performed in the Gulou Hospital Affiliated to Medical College of Nanjing University from January 2010 to March 2015 were retrospectively investigated for analysis HBV and HCV infection rate.The clinical testing data of 866 SLE inpatients (SLE group)from January 2010 to March 2015 were retrospectively in-vestigated for analysis HBV and HCV infection rate.The serological tests performed in 1 795 health examination people (Control group)to estimate the HBV and HCV infection ratein general population using ELISA.Compare the difference of HBV/HCV infection rate between SLE group and Control group.Results In the SLE group,17 patients were HBsAg posi-tive,the positive rate was 1.96%.In the control group HBsAg postive 204 patients,the positive rate was 11.4%,there were significant differences between these two groups (χ2 =67.81,P <0.0001).The HBsAg positive rate was lower in male SLE patients compared with controls (5.26% VS 13.9%,χ2 =4.58,P <0.05).For the female SLE patients,the HBsAg positive rate was significantly lower than the control (1.64% VS 8.12%,χ2 = 35.65,P <0.0001).The HBsAg positive rate was lower in SLE group compared with control group among different age groups,and the difference was significant in 21~30, 31~40 and 41~50 age group (χ2 =21.86,22.78,20.36;all P <0.001).There had no statistical difference between SLE and control group for the HBsAb positive rate(Total,χ2 =0.50,P =0.48;Male,χ2 =0.12,P =0.73;Female,χ2 =2.00,P =0.16).Conclusion The prevalence of HBV infection in SLE patients was lower than general population.

OBJECTIVE: To evaluate the cost-effectiveness of 3 therapeutic schemes in the treatment of chronic Hepatitis B with YMDD mutation.METHODS: 90 patients were randomly assigned into three groups: the patients in Group A were assigned to receive Adefovir Dipivoxil in combination with Lamivudine for 12 weeks followed by administration of Adefovir alone for 36 weeks;Group B received Adefovir in combination with Lamivudine for 48 weeks,while Group C received Entecavir alone for 48 weeks.The cost-effectiveness of the 3 groups were analyzed.RESULTS: In the three groups(A,B,and C),the cost-effectiveness ratios for HBV DNA negative-conversion ratewere 12 685.6,15 481.3,and 31 462.2,respectively and the incremental cost-effectiveness ratios of Group B and Group C were 29 501.5 and 106 907.8 respectively as against Group A.The cost-effectiveness ratios of the three Groups(A,B,and C) for serum alanine aminotransferase normalization rate were 12 685.6,14 284.9,31 462.2 respectively,and the incremental cost-effectiveness ratios of Group B and Group C were 19 618.5 and 106 907.8 respectively as against Group A.The cost-effectiveness ratios of the three Groups(A,B,and C) for HBeAg/HBeAb seroconversion rate were 76 227.9,93 120.3,and 209 664.0 respectively,and the incremental cost-effectiveness ratios of Group B and Group C were 178 350.0 and 1 267 621.4 respectively as against Group A.In Group A,1 case showed rtA181V mutation and another one showed rtN236T mutation after 48-week treatment.CONCLUSION: Group B(ADV in combination with LAM) is more cost-effective in the treatment of chronic hepatitis B with YMDD mutation.

0.05).At week 52,there was significant difference in the undetectable HBV DNA rate between group C and group B(P0.05),and the rate of drug resistant genotype was 21.9%(7/32)、0、0(P